Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

Pfizer

Status and phase

Completed

Phase 3

Conditions

Glioblastoma

Treatments

Drug: Lomustine (CCNU)

Drug: Edotecarin

Drug: Carmustine (BCNU)

Drug: Temozolomide

Study type

Interventional

Funder types

Industry

Identifiers

NCT00068952

EDOAGL-8725-001

A5921009

Details and patient eligibility

About

The purpose of this clinical trial is to study Edotecarin in patients with the brain tumor glioblastoma multiforme (GBM) who have progression or first recurrence following initial treatment with surgery, radiation and chemotherapy.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Must have biopsy-proven GBM. First relapse (progression or recurrence) of GBM after surgery (or biopsy) and treatment with radiotherapy (conventional fractionated external beam) and chemotherapy (temozolomide- or nitrosurea-based therapy)
Must have past biopsy samples available for central pathology review
Must have evidence on Gd-MRI of progressive/recurrent disease
Must have measurable disease on Gd-MRI obtained within 14 days prior to start of study treatment
Must be at least 18 years of age
Must have a Karnofsky Performance Status score of at least 70
If being treated with steroids, the steroid dose must be stable or decreasing for 1 week prior to randomization
If being treated with anticonvulsants, must have no change in the type of anticonvulsants for 2 weeks prior to randomization
All acute toxic effects (except for alopecia) of any prior treatment must have resolved or are no greater than grade 1 (NCI Common Toxicity Criteria, Version 2.0)
Baseline laboratory data must be within the following limits: absolute neutrophil count at least 1500; platelets at least 100,000; hemoglobin at least 9.0 g/dL; serum creatinine no greater than 1.5 mg/dL, total serum bilirubin no greater than 1.5 times the upper limit of the normal range; SGOT and SGPT no greater than 2.5 times the upper limit of the normal range; albumin at least 3.0 g/dL, serum or urine pregnancy test (for females of childbearing potential) negative within 7 days prior to start of study treatment
At least 6 weeks must have elapsed since completion of prior nitrosurea therapy; at least 4 weeks since completion of prior temozolomide therapy
Must have written informed consent
Must be able and willing to comply with study procedures
	Must have received prior treatment with radiotherapy (conventional fractionated external beam) and (neo)adjuvant/concurrent chemotherapy (with a temozolomide- or a nitrosurea-based containing )regimen for GBM

Exclusion criteria

Must not have received prior treatment (except for surgical debulking) of first relapse (progression or recurrence) of GBM
Must not have received prior treatment with another topoisomerase-I inhibitor (e.g. irinotecan, topotecan, rubitecan)
Must not have had radiosurgery or radiotherapy within 1 month prior to randomization
Must not have had prior brachytherapy or chemotherapy wafer implantation
Must not have had prior high-dose chemotherapy with bone marrow or stem cell support
Must not receive concomitant treatment with any other investigational agent or anti-cancer treatment during the study
Must not be currently enrolled in another therapeutic clinical trial for the treatment of GBM
Must not currently (or in the past 5 years) have other malignancies (except for adequately treated basal cell or squamous cell skin cancer or non-invasive cervical cancer)
Must not have any of the following in the past 6 months: myocardial infarction (heart attack), severe/unstable angina, coronary artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident (stroke), or transient ischemic attack (TIA)
Must not have had any of the following in the past 2 months: pulmonary embolus (blood clot in lungs), deep venous thrombosis (blood clot in veins), or other significant thromboembolic event
Must not have an ongoing cardiac dysrhythmia (abnormal heart rhythm) of grade 2 or higher (NCI Common Toxicity Criteria, Version 2.0)
Must not have known human immunodeficiency virus (HIV) infection
Must not be pregnant or breastfeeding. Patients (male and female) must be surgically sterile (or postmenopausal for females) or must agree to use effective contraception during the period of study treatment
Must not be inappropriate for entry into the study, in the judgment of the investigator